Black Diamond TherapeuticsNASDAQ: BDTX

BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass.

Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health

Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.

Black Diamond (BDTX) passed our "Recent Price Strength" screen and may be an excellent option for investors seeking to capitalize on stocks that are currently gaining momentum.

Analysts' average price target for Black Diamond suggests a 153% increase in the stock. Although this metric is not always reliable, the consensus among analysts in increasing earnings estimates does suggest potential upside for the stock.

There is a possibility that Black Diamond (BDTX) could increase in value due to increasing confidence in its earnings potential, as evidenced by its upgrade to a Zacks Rank #2 (Buy).

The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.